Economic burden and treatment patterns for patients with diffuse large B-cell lymphoma and follicular lymphoma in the USA

被引:24
作者
Ren, Jinma [1 ]
Asche, Carl V. [1 ,2 ]
Shou, Yaping [3 ]
Galaznik, Aaron [3 ]
机构
[1] Univ Illinois, Coll Med Peoria, Dept Med, Ctr Outcomes Res, Peoria, IL 61656 USA
[2] Univ Illinois, Coll Pharm, Ctr Pharmacoepidemiol & Pharmacoecon Res, Chicago, IL USA
[3] Millennium Pharmaceut Inc, Cambridge, MA USA
关键词
diffuse large B-cell lymphoma; follicular lymphoma; healthcare costs; resource utilization; treatment; NON-HODGKINS-LYMPHOMA; RITUXIMAB MAINTENANCE; COST-EFFECTIVENESS; ELDERLY-PATIENTS; TRANSPLANTATION; THERAPY; CHEMOTHERAPY; SURVIVAL; EFFICACY;
D O I
10.2217/cer-2018-0094
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Aim: Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) are common types of non-Hodgkin's lymphoma, and real-world evidence continues to be lacking for healthcare costs and utilization among DLBCL and FL patients. Our study aims to describe medical and pharmacy costs and health resource utilization and to characterize longitudinal treatment patterns among these patients. Methods: A retrospective observational study was performed among adult patients with DLBCL or FL using the US MarketScan (Truven) administrative claims data from 1 January 2007 to 31 December 2015. Diagnoses of DLBCL and FL were based upon ICD-9 codes. Identifications of treatment lines involved 30 lymphoma-specific anticancer systemic agents. Direct healthcare costs and utilizations were computed in the 1-year postdiagnosis period. Generalized linear models with a gamma link were used to compare healthcare costs between therapies with and without rituximab. Results: A total of 2767 DLBCL and 5989 FL patients received frontline therapy. The majority received treatment within 3 months after initial diagnosis (DLBCL 79.9% and FL 62.4%) and were treated with rituximab or bendamustine either alone or in combination (DLBCL 67.4% and FL 84.7%). The total healthcare costs were US $15,555 and $10,192 per patient per month within 1 year following their initial diagnosis for DLBCL and FL, respectively. The medical costs were nearly twice as much as the drug costs for DLBCL patients. Both DLBCL and FL patients receiving rituximab had higher pharmacy costs but lower medical costs (p < 0.001). During the first year following initial diagnosis, the resource utilization (per patient per month) of DLBCL patients included 0.21 inpatient admissions, 0.26 radiation therapy, 2.63 outpatient or office visits, 0.18 emergency room visits, 0.06 intensive care unit admissions and 0.10 stem cell transplantation. FL patients occupied less health resources than DLBCL patients. Conclusion: The healthcare costs and health resources utilized were considerable in non-Hodgkin's lymphoma, especially DLBCL patients.
引用
收藏
页码:393 / 402
页数:10
相关论文
共 26 条
[1]   Autologous Stem Cell Transplantation in Follicular Lymphoma: a Systematic Review and Meta-analysis [J].
Al Khabori, Murtadha ;
de Almeida, John R. ;
Guyatt, Gordon H. ;
Kuruvilla, John ;
Crump, Michael .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2012, 104 (01) :18-28
[2]  
American Cancer Society, 2017, TYP NONH LYMPH
[3]  
Amin AD, 2017, CSH MOL CASE STUD, V3, DOI 10.1101/mcs.a001719
[4]   Comparing the Cost-Effectiveness of Rituximab Maintenance and Radioimmunotherapy Consolidation versus Observation Folio First-Line Therapy in Patients with Follicular Lymphoma [J].
Chen, Qiushi ;
Ayer, Turgay ;
Nastoupil, Loretta J. ;
Rose, Adam C. ;
Flowers, Christopher R. .
VALUE IN HEALTH, 2015, 18 (02) :189-197
[5]   CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. [J].
Coiffier, B ;
Lepage, E ;
Brière, J ;
Herbrecht, R ;
Tilly, H ;
Bouabdallah, R ;
Morel, P ;
Van den Neste, E ;
Salles, G ;
Gaulard, P ;
Reyes, F ;
Gisselbrecht, C .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (04) :235-242
[6]   Life expectancy of young adults with follicular lymphoma [J].
Conconi, A. ;
Lobetti-Bodoni, C. ;
Montoto, S. ;
Lopez-Guillermo, A. ;
Coutinho, R. ;
Matthews, J. ;
Franceschetti, S. ;
Bertoni, F. ;
Moccia, A. ;
Rancoita, P. M. V. ;
Gribben, J. ;
Cavalli, F. ;
Gaidano, G. ;
Lister, T. A. ;
Montserrat, E. ;
Ghielmini, M. ;
Zucca, E. .
ANNALS OF ONCOLOGY, 2015, 26 (11) :2317-2322
[7]   Rituximab maintenance therapy of follicular lymphoma in clinical practice [J].
Duehrsen, Ulrich ;
Broszeit-Luft, Stefanie ;
Dieing, Annette ;
Lueck, Andreas ;
Porowski, Piotr ;
Reiser, Marcel ;
Schwinger, Ulrike ;
Klawitter, Sandra ;
Krumm, Katja ;
Jentsch-Ullrich, Kathleen .
CANCER MEDICINE, 2018, 7 (07) :2903-2912
[8]   Economic Burden of Follicular Non-Hodgkin's Lymphoma [J].
Foster, Talia ;
Miller, Jeffrey D. ;
Boye, Mark E. ;
Russell, Mason W. .
PHARMACOECONOMICS, 2009, 27 (08) :657-679
[9]   Relapsed/Refractory Diffuse Large B-Cell Lymphoma [J].
Friedberg, Jonathan W. .
HEMATOLOGY-AMERICAN SOCIETY HEMATOLOGY EDUCATION PROGRAM, 2011, :498-505
[10]   Comparative Effectiveness and Cost of Adding Rituximab to First-Line Chemotherapy for Elderly Patients Diagnosed With Diffuse Large B-Cell Lymphoma [J].
Griffiths, Robert I. ;
Gleeson, Michelle L. ;
Mikhael, Joseph ;
Dreyling, Martin H. ;
Danese, Mark D. .
CANCER, 2012, 118 (24) :6079-6088